National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 4)(No. PB 34 of 2011) (Cth)
PB 34 of 2011
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2011 (No. 4)
National Health Act 1953
___________________________________________________________________________
I, FELICITY MCNEILL, Acting First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated 20 April 2011
FELICITY MCNEILL
Acting First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________________
1 Name of Instrument
(1)This Instrument is the National Health (Highly
specialised drugs program for hospitals) Special Arrangement
Amendment Instrument 2011 (No.4).
(2)This Instrument may also be cited as PB 34 of 2011.
2 Commencement
This Instrument commences on 1 May 2011.
3 Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010)
.
Schedule 1 Amendments
[1] Schedule 1, after entry for Lenograstim in the form Powder for injection 33,600,000 I.U. (263 micrograms)
insert in the columns in the order indicated:
| Levodopa with Carbidopa | Intestinal gel 20 mg-5 mg per mL ,100 mL | Intra-intestinal | Duodopa | AB | EMP | C3704 C3705 | 56 | 5 | D |
Schedule 1, entry for Tocilizumab in the form Concentrate for injection 400 mg in 20 mL
substitute:
| Concentrate for injection 400 mg in 20 mL | Injection | Actemra | RO | EMP | C3480 C3559 C3560 C3561 | See Note 1 | See Note 2 | D |
Schedule 1, entry for Valaciclovir in the form Tablet 500 mg (as hydrochloride)
insert in the columns in the order indicated, in alphabetical order by brand:
| Zelitrex | RE | EMP | C1494 C3419 | 500 | 2 | D |
[4] Schedule 2
after:
| PF | Pfizer Australia Pty Ltd | 50 008 422 348 |
insert:
| RE | GlaxoSmithKline Australia Pty Ltd | 47 100 162 481 |
[5] Schedule 3, after entry for Lenograstim
insert in the columns in the order indicated:
| Levodopa with Carbidopa | C3704 | Where the patient is receiving treatment at/from a public hospital Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy. Treatment must be commenced in a hospital-based movement disorder clinic | Compliance with Written or Telephone Authority Required procedures – Streamlined Authority Code 3704 |
| C3705 | Where the patient is receiving treatment at/from a private hospital Management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy. Treatment must be commenced in a hospital-based movement disorder clinic | Compliance with Written or Telephone Authority Required procedures |
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0